US 12,441,792 B2
Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof
Michael A. Meehl, Northborough, MA (US); Philip E. Brandish, Needham, MA (US); Laurence Fayadat-Dilman, Sunnyvale, CA (US); Veronica Juan, Redwood City, CA (US); Carl Mieczkowski, Hercules, CA (US); and Latika Singh, Belmont, MA (US)
Assigned to Merck Sharp & Dohme LLC, Rahway, NJ (US)
Filed by Merck Sharp & Dohme Corp., Rahway, NJ (US)
Filed on Jul. 16, 2021, as Appl. No. 17/378,050.
Application 17/378,050 is a division of application No. 16/191,485, filed on Nov. 15, 2018, granted, now 11,111,297.
Claims priority of provisional application 62/587,604, filed on Nov. 17, 2017.
Prior Publication US 2022/0010010 A1, Jan. 13, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2803 (2013.01) [A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/32 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 13 Claims
 
1. A method for treating a subject having a cancer, comprising administering to the subject a therapeutically effective amount of an antibody or antigen binding fragment thereof that binds the extracellular domain of human immunoglobulin-like transcript 3 (ILT3) having amino acids 1-238 of SEQ ID NO: 1, wherein the antibody or antigen binding fragment thereof comprises:
(a) a heavy chain complementarity determining region 1 (HC-CDR1), wherein the HC-CDR1 has the amino acid sequence set forth in SEQ ID NO: 17; an HC-CDR2, wherein the HC-CDR2 has the amino acid sequence set forth in SEQ ID NO: 20; an HC-CDR3, wherein the HC-CDR3 has the amino acid sequence set forth in SEQ ID NO: 23; and
(b) a light chain complementarity determining region 1 (LC-CDR1), wherein the LC-CDR1 has the amino acid sequence set forth in SEQ ID NO: 41; an LC-CDR2, wherein the LC-CDR2 has the amino acid sequence set forth in SEQ ID NO: 43; and an LC-CDR3, wherein the LC-CDR3 has the amino acid sequence set forth in SEQ ID NO: 44,
wherein the cancer is sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, or carcinoma, and wherein the treatment overcomes tumor-specific tolerance.